19:24 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Acceleron, Celgene score second win with latest luspatercept readout

Acceleron Pharma Inc. (NASDAQ:XLRN) climbed $1.36 to $48.76 July 10 after it and partner Celgene Corp. (NASDAQ:CELG) said luspatercept (ACE-536) met the primary endpoint in the Phase III BELIEVE study to treat beta-thalassemia. The companies...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other molecule...
21:31 , Dec 19, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles based on A. fulgidus ferritin could deliver thermally and/or chemically labile proteins to help treat cancer and other diseases. The nanoparticles consist of 23 recombinant A. fulgidus ferritin subunits -- including one fused...
20:55 , Jul 27, 2017 |  BC Innovations  |  Translation in Brief

Sepsis' sweet tooth

It has long been known that pathogens rely on their host to provide metabolites and metals like iron to support growth and infections. Now, scientists from the Gulbenkian Institute of Science have shown how iron...
21:04 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Mouse studies suggest ferritin or promoting FTH1 expression could help treat sepsis. In a mouse model of cecal ligation and puncture (CLP)-induced sepsis, adenoviral-mediated overexpression of FTH1 in the liver or IV injection of...
23:31 , Jun 22, 2017 |  BC Week In Review  |  Clinical News

Acceleron, Celgene complete enrollment in Phase III of luspatercept in beta-thalassemia

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corp. (NASDAQ:CELG) completed enrollment of 300 patients with transfusion-dependent beta-thalassemia in the Phase III BELIEVE trial evaluating subcutaneous luspatercept (ACE-536) every 3 weeks for 48 weeks. The companies expect...
23:30 , Jun 22, 2017 |  BC Week In Review  |  Clinical News

Acceleron, Celgene complete enrollment in Phase III of luspatercept in MDS

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corp. (NASDAQ:CELG) completed enrollment of 210 patients with ring sideroblasts (RS+), lower-risk myelodysplastic syndrome (MDS) in the Phase III MEDALIST trial evaluating subcutaneous luspatercept (ACE-536) every 3 weeks for...
18:41 , Jan 11, 2017 |  BC Week In Review  |  Clinical News

Ferritin IVD Capsule test regulatory update

Abionic received CE mark approval for its Ferritin IVD Capsule test to diagnose iron deficiency. The company plans to launch the product early this year. The test measures ferritin levels in blood and runs on...
11:42 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-ND trial to compare oral daprodustat once daily vs. subcutaneous darbepoetin alfa in about 4,500 non-dialysis-dependent patients switching from, or are naïve to, an erythropoietin-stimulating agent (ESA). Patients...
11:42 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-D trial to compare oral daprodustat once daily vs. subcutaneous or IV darbepoetin alfa in about 3,000 dialysis patients switching from an erythropoietin-stimulating agent (ESA). Patients will have...